Previous close | 0.3715 |
Open | 0.3651 |
Bid | 0.3300 x 1000 |
Ask | 0.0000 x 900 |
Day's range | 0.3651 - 0.3940 |
52-week range | 0.2300 - 4.6000 |
Volume | |
Avg. volume | 1,347,369 |
Market cap | 6.019M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.1820 |
Earnings date | 11 Aug 2022 - 15 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
HOUSTON, July 12, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company’s Vice President of Research & Development and Clinic
HOUSTON, July 07, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the timely completion of construction on its expanded current good manufacturing practice (cGMP) manufacturing facility in Houston. This significant milestone was accomplished within the time
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on June 23, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-minu